NICHE-2: Neoadjuvant ipilimumab-nivolumab yields 100% survival in dMMR colon cancer
Start here
The Dutch phase 2 NICHE-2 trial tested two doses of ipilimumab plus nivolumab before surgery in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer. Results published in The Lancet show 3-year disease-free survival and 5-year overall survival of 100% in this single-arm, multicentre study. Based on these outcomes, the investigators propose the neoadjuvant combination as a potential standard of care for locally advanced dMMR colon cancer. Open questions include confirmation in randomized settings and broader adoption into clinical guidelines.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- The LancetPick[Articles] Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
The Dutch single-arm, multicentre, phase 2 NICHE-2 trial showed that patients with locally advanced dMMR colon cancer who received ipilimumab and nivolumab before surgery had 3-year disease-free survival and 5-year overall survival of 100%. The authors consider that this neoadjuvant combination may become a standard treatment option for locally advanced dMMR colon cancer.
Coverage and heat for this story
Reports so far 2·Heat now 9·Peak heat 10 (Oct 22 07:00)·Reports, 24h +2
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.